| 1.46 0.01 (0.69%) | 05-14 15:11 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.93 | 1-year : | 2.13 |
| Resists | First : | 1.65 | Second : | 1.83 |
| Pivot price | 1.5  |
|||
| Supports | First : | 1.37 | Second : | 1.13 |
| MAs | MA(5) : | 1.48 |
MA(20) : | 1.55 |
| MA(100) : | 1.59 |
MA(250) : | 1.83 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 28.6 |
D(3) : | 24.2 |
| RSI | RSI(14): 50.3 |
|||
| 52-week | High : | 3.44 | Low : | 1.21 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ BYSI ] has closed below upper band by 31.2%. Bollinger Bands are 26% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.62 - 1.63 | 1.63 - 1.64 |
| Low: | 1.41 - 1.42 | 1.42 - 1.43 |
| Close: | 1.44 - 1.45 | 1.45 - 1.46 |
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody for the treatment of SCLC; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York.
Wed, 13 May 2026
BeyondSpring (NASDAQ: BYSI) swings to $6.7M net loss as SEED ops weigh - Stock Titan
Wed, 13 May 2026
BeyondSpring (BYSI) Q1 2026 Results: EPS -$0.05, Revenue $0 -- H - GuruFocus
Wed, 13 May 2026
BeyondSpring Releases Q1 2026 Financial Results - AlphaStreet
Wed, 13 May 2026
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Wed, 13 May 2026
BeyondSpring Inc. (BYSI) Reports Q1 Loss of $0.06 - StreetInsider
Wed, 13 May 2026
BeyondSpring reports Q1 2026 results: $2.4M continuing net loss, $7.9M cash & short-term investments - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 41 (M) |
| Shares Float | 32 (M) |
| Held by Insiders | 14.8 (%) |
| Held by Institutions | 14.5 (%) |
| Shares Short | 2,190 (K) |
| Shares Short P.Month | 2,190 (K) |
| EPS | -0.21 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.81 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -18.6 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.22 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -20 (M) |
| Levered Free Cash Flow | 15 (M) |
| PE Ratio | -7.43 |
| PEG Ratio | 0 |
| Price to Book value | -1.95 |
| Price to Sales | 0 |
| Price to Cash Flow | -3.25 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|